Ascendis Pharma is projected to see continued growth in revenue over the next few years, making it a promising investment opportunity for long-term investors.
Bears say
Ascendis Pharma is facing fierce competition in the biopharmaceutical industry and their current product pipeline does not seem strong enough to maintain their position in the market. The recent launch of Yuviwel seems promising, but it may not be sustainable in the long term due to ongoing legal disputes and uncertainty surrounding future expenses and revenues. Additionally, the Ph3 combo study set to begin in late-2026 does not provide a near-term solution for revenue growth, posing a high level of risk for this stock.
Ascendis Pharma (ASND) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 59% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Ascendis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Ascendis Pharma (ASND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Ascendis Pharma (ASND) a Buy based on their latest research and market trends.
According to 17 analysts, Ascendis Pharma (ASND) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $298.29, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $298.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Ascendis Pharma (ASND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.